HANDA THERAP
PharmaHANDA THERAP is a pharmaceutical company focused on Oncology. Key products include PHYRAGO.
HANDA THERAP's Key Drugs
HANDA THERAP's core commercial portfolio centers on PHYRAGO, spanning Oncology — its most strategically important drugs approved in the last 15 years.
HANDA THERAP's Recent FDA Approvals
New NDA/BLA approvals for HANDA THERAP over the last two years — novel drugs only, excluding generics and label supplements.
HANDA THERAP's Therapeutic Areas
HANDA THERAP's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HANDA THERAP's Top Competitors
HANDA THERAP's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HANDA THERAP Pipeline Snapshot
Active clinical trials for HANDA THERAP across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PHYRAGO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2023-12-05
- Latest
- 2025-08-01
- Applications
- 1